KRAS and non-small cell lung carcinoma: A retrospective study of 174 KRAS-mutated NSCLC patients, including 31% with STK11/LKB1 co-mutation, demonstrated significantly lower ORR and PFS following PD-1 inhibitor therapy in STK11/LKB1-co-mutated patients compared with STK11/LKB1-wild-type patients [140].